Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Starting soon · Phase 3

Conditions studied: Steno-occlusive Disease

In brief

Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI

Key facts

Study ID: NCT07348640
Run by: Guerbet
People needed: 315
Starts: 2026-02-02
Expected to finish: 2027-12-31
Last updated by the study team: 2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patients 18 years of age or older willing to participate in the trial and follow all study procedures specified in the protocol.
Patient having read the information in the ICF and having provided his/her consent to participate in writing by dating and signing the ICF prior to any trial related procedure being conducted.
Patient with suspected steno-occlusive disease in supra-aortic (carotid/vertebrobasilar) (a), peripheral (b) or abdominal/renal (c) arteries based on:
clinical signs and symptoms including but not limited to prior stroke, transient ischemic attack (TIA), amaurosis fugax (transient monocular blindness) and/or previous diagnostic tests (CTA, IA-DSA, or ultrasound) or
symptoms of lower-extremity arterial disease (stages II-IV according to the Leriche-Fontaine classification, or 1 to 6 according to Rutherford classification 113 and/or confirmed by previous imaging (Doppler ultrasound, CTA, MRA, IADSA) or
suspected renovascular hypertension based on one or more of the following criteria:
i. hypertension refractory to standard therapy ii. acute worsening of pre-existing hypertension iii. abrupt onset of sustained, moderate to severe hypertension at age <35 years suggestive of fibromuscular dysplasia (FMD) iv. progressive renal insufficiency (creatinine > 2 mg/dL; no other apparent cause of progressive renal failure based on routine medical history, physical examination, 24-h urine collection and urinary protein excretion) v. abnormal/inconclusive renal doppler ultrasound. vi. other criteria (to be specified)
Are scheduled for or had undergone CTA and/or IA-DSA according to imaging standards to cover the supra-aortic (carotid/vertebrobasilar) and/or peripheral and/or abdominal/renal territory described in this protocol.

You may not qualify if…

Is a pregnant or lactating female. Exclude the possibility of pregnancy for women of childbearing potential:
by testing on site at the institution (serum βHCG or urine)
by surgical history (e.g., tubal ligation or hysterectomy)
post-menopausal with a minimum 1 year without menses.
Has any known allergy to one or more of the ingredients in the investigational products or has a history of hypersensitivity to other GBCAs.
Has severe renal impairment defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Has known or suspected acute kidney injury (AKI) based on: a. Increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours or b. Increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within prior 7 days or c. Urine volume < 0.5 mL/kg/h for 6 hours
Has received any contrast agent (for MRI, CT, DSA) prior to the first IMP administration or is scheduled to receive any contrast agent between the two MRA or after the second IMP administration.
Has received or is scheduled for therapeutic intervention (e.g., endovascular therapy, vascular surgery, etc.) of any kind for vascular disease in the arterial territory of interest performed between the 2 MRA procedures or between the study MRAs and the CTA/IADSA procedures when applicable.
Has any contraindications to MRI.
Is suffering from severe claustrophobia.
Has received an investigational drug or medical device before admission into this study or scheduled to receive any investigational treatment in the course of the trial.
Was previously included in this trial.
Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.

Where it is running

University of California Los Angeles (UCLA) — Los Angeles, California, United States
UCHealth University of Colorado Hospital — Aurora, Colorado, United States
Northshore - Evanston Hospital — Evanston, Illinois, United States
Mayo Clinic — Rochester, Minnesota, United States
Houston Methodist Hospital — Houston, Texas, United States
University of Washington — Seattle, Washington, United States
Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada
Department of Radiology and Nuclear Medicine, University Hospital Brno — Brno, Czechia
Motol University Hospital — Prague, Czechia
CHU Hopitaux de Bordeaux - Groupe Hospitalier Pellegrin — Bordeaux, France
Hôpital Cardiovasculaire et Pneumologique — Bron, France
CHU Dijon Bourgogne — Dijon, France
CHU de Poitiers — Poitiers, France
Charité - Universitätsmedizin Berlin — Berlin, Germany
University Hospital Bonn — Bonn, Germany
UH Essen — Essen, Germany
University Hospital of Saarland — Homburg, Germany
Klinik fuer Diagnostische Radiologie and Neuroradiologie — Kiel, Germany
Department of Neuroradiology, UKSH Campus Lübeck — Lübeck, Germany
LMU University Hospital — München, Germany
Semmelweis University - Budapest — Budapest, Hungary
University of Debrecen - Debrecen — Debrecen, Hungary
University of Pecs Clinical Centre — Pécs, Hungary
Reparto di Neuroradiologia ASST Ospedale Papa Giovanni XXIII — Bergamo, Italy
Azienda Ospedaliera di Monserrato — Cagliari, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.